Companies › Lantern Pharma
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LP-300 Mesna analogue; protective agent against chemotherapy-induced toxicity | – | Phase 2 | Adenocarcinoma of Lung | Dec 2026 |
| LP-284 Small molecule alkylating agent causing tumor cell death through DNA damage | – | Phase 1 | Relapsed or Refractory Lymphomas | Nov 2028 |
| LP-184 Small molecule alkylating agent causing tumor cell death through DNA damage | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05933265 | LP-184 | Phase 1 | Advanced Solid Tumor | Oncology | Jul 2026 |
| NCT05456256 | LP-300 | Phase 2 | Adenocarcinoma of Lung | Oncology | Dec 2026 |
| NCT06132503 | LP-284 | Phase 1 | Relapsed or Refractory Lymphomas | Oncology | Nov 2028 |
Cash and short-term investments of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 6 months at that burn, to Jan 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Neonc Technologies Bio-Path Holdings Inhibrx Biosciences Immuneering Oncolytics Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.